Literature DB >> 22160886

Preparation, characterization, and in vitro intestinal permeability evaluation of thalidomide-hydroxypropyl-β-cyclodextrin complexes.

Jadel M Kratz1, Marina R Teixeira, Karine Ferronato, Helder F Teixeira, Letícia S Koester, Cláudia M O Simões.   

Abstract

Thalidomide is emerging as a therapeutic agent with renewed clinical importance, presenting anti-inflammatory, immunomodulatory, and antineoplasic properties. In this work, we studied the complexation of thalidomide with cyclodextrins as a strategy to circumvent the poor aqueous solubility of the drug. Thalidomide-hydroxypropyl-β-cyclodextrin complexes were obtained by kneading method and were characterized by differential scanning calorimetry, powder X-ray diffractometry, and scanning electronic microscopy. The aqueous solubility and in vitro dissolution of thalidomide were significantly improved through the complexation. Physicochemical analysis of the complexes in solid state revealed a decreased crystallinity of the complexed drug in comparison with free thalidomide. Thalidomide was able to dissociate from the complexes and permeates across intestinal epithelial Caco-2 cells with a favorable high permeability profile equivalent to that of the free drug. In summary, the present results suggest that thalidomide-hydroxypropyl-β-cyclodextrin complexes could be regarded as a promising strategy for improving the gastrointestinal absorption of thalidomide.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22160886      PMCID: PMC3299449          DOI: 10.1208/s12249-011-9739-2

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  36 in total

Review 1.  Cyclodextrins in drug delivery.

Authors:  Thorsteinn Loftsson; Pekka Jarho; Már Másson; Tomi Järvinen
Journal:  Expert Opin Drug Deliv       Date:  2005-03       Impact factor: 6.648

Review 2.  2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review.

Authors:  Sarah Gould; Robert C Scott
Journal:  Food Chem Toxicol       Date:  2005-04-19       Impact factor: 6.023

Review 3.  Properties of thalidomide and its analogues: implications for anticancer therapy.

Authors:  Steven K Teo
Journal:  AAPS J       Date:  2005-03-22       Impact factor: 4.009

4.  Thalidomide does not interact with P-glycoprotein.

Authors:  Christian Zimmermann; Heike Gutmann; Juergen Drewe
Journal:  Cancer Chemother Pharmacol       Date:  2005-09-01       Impact factor: 3.333

5.  Preparation of celecoxib-dimethyl-beta-cyclodextrin inclusion complex: characterization and in vitro permeation study.

Authors:  Cinzia Anna Ventura; Ignazio Giannone; Donatella Paolino; Venerando Pistarà; Antonino Corsaro; Giovanni Puglisi
Journal:  Eur J Med Chem       Date:  2005-04-02       Impact factor: 6.514

Review 6.  Cyclodextrins and their pharmaceutical applications.

Authors:  Thorsteinn Loftsson; Dominique Duchêne
Journal:  Int J Pharm       Date:  2006-11-09       Impact factor: 5.875

7.  Influence of cyclodextrins and chitosan, separately or in combination, on glyburide solubility and permeability.

Authors:  N Zerrouk; G Corti; S Ancillotti; F Maestrelli; M Cirri; P Mura
Journal:  Eur J Pharm Biopharm       Date:  2005-10-14       Impact factor: 5.571

8.  Effects of gamma- and hydroxypropyl-gamma-cyclodextrins on the transport of doxorubicin across an in vitro model of blood-brain barrier.

Authors:  V Monnaert; D Betbeder; L Fenart; H Bricout; A M Lenfant; C Landry; R Cecchelli; E Monflier; S Tilloy
Journal:  J Pharmacol Exp Ther       Date:  2004-07-27       Impact factor: 4.030

Review 9.  The thalidomide saga.

Authors:  Magda Melchert; Alan List
Journal:  Int J Biochem Cell Biol       Date:  2007-01-30       Impact factor: 5.085

Review 10.  Effects of cyclodextrins on drug delivery through biological membranes.

Authors:  Thorsteinn Loftsson; Stine Byskov Vogensen; Marcus E Brewster; Fífa Konrádsdóttir
Journal:  J Pharm Sci       Date:  2007-10       Impact factor: 3.534

View more
  6 in total

1.  Experimental and computational studies of physicochemical properties influence NSAID-cyclodextrin complexation.

Authors:  Linda A Felton; Carmen Popescu; Cody Wiley; Emilio Xavier Esposito; Philippe Lefevre; Anton J Hopfinger
Journal:  AAPS PharmSciTech       Date:  2014-04-10       Impact factor: 3.246

2.  Cholecalciferol complexation with hydroxypropyl-β-cyclodextrin (HPBCD) and its molecular dynamics simulation.

Authors:  Fang Wang; Wenbo Yu; Carmen Popescu; Ahmed Ashour Ibrahim; Dongyue Yu; Ryan Pearson; Alexander D MacKerell; Stephen W Hoag
Journal:  Pharm Dev Technol       Date:  2022-04-25       Impact factor: 3.915

3.  Losartan Interactions with 2-Hydroxypropyl-β-CD.

Authors:  Vasiliki Palli; Georgios Leonis; Nikoletta Zoupanou; Nikitas Georgiou; Maria Chountoulesi; Nikolaos Naziris; Demeter Tzeli; Costas Demetzos; Georgia Valsami; Konstantinos D Marousis; Georgios A Spyroulias; Thomas Mavromoustakos
Journal:  Molecules       Date:  2022-04-08       Impact factor: 4.927

4.  Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia.

Authors:  G Colombo; F Bortolotti; V Chiapponi; F Buttini; F Sonvico; R Invernizzi; F Quaglia; C Danesino; F Pagella; P Russo; R Bettini; P Colombo; A Rossi
Journal:  Int J Pharm       Date:  2016-11-30       Impact factor: 5.875

Review 5.  Cyclodextrin⁻Drug Inclusion Complexes: In Vivo and In Vitro Approaches.

Authors:  Simone Braga Carneiro; Fernanda Ílary Costa Duarte; Luana Heimfarth; Jullyana de Souza Siqueira Quintans; Lucindo José Quintans-Júnior; Valdir Florêncio da Veiga Júnior; Ádley Antonini Neves de Lima
Journal:  Int J Mol Sci       Date:  2019-02-02       Impact factor: 5.923

6.  Improvement of Physico-mechanical Properties of Partially Amorphous Acetaminophen Developed from Hydroalcoholic Solution Using Spray Drying Technique.

Authors:  Fatemeh Sadeghi; Mansour Torab; Mostafa Khattab; Alireza Homayouni; Hadi Afrasiabi Garekani
Journal:  Iran J Basic Med Sci       Date:  2013-10       Impact factor: 2.699

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.